AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12547873 — intervention group
Group type: COMPARATOR
Intervention: HIM2 (0.5 and 1.0 mg/kg)
Number of subjects: 18
Study 10883417 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-450 200 micrograms
Number of subjects: 28
Study 10883417 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-450 300 micrograms
Number of subjects: 28
Study 10883417 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-450 200 micrograms and 300 micrograms
Number of subjects: 28
Study 10883417 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-450
Number of subjects: 28
Study 8938913 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 200 mg/day (withdrawn abruptly)
Number of subjects: 30
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 single oral dose on day 8
Number of subjects: 25
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 and 120 mg/m2 single oral doses on days 8 and 15
Number of subjects: 25
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/m2 and 240 mg/m2 single oral doses on days 8 and 15
Number of subjects: 25
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 single oral doses on 5 consecutive days from days 8 to 12
Number of subjects: 25
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 three times a day at 6-hour intervals on day 8
Number of subjects: 25
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg/m2 single oral dose
Number of subjects: 25
Study 1411636 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses on 1 day or 5 consecutive days
Number of subjects: 25
Study 3907642 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 34
Study 3907642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 30260551 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic (SIL) surgery
Number of subjects: 50
Study 30260551 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic (CL) surgery
Number of subjects: 50
Study 30571332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic acid+docosahexaenoic acid; 8‐10 g for 2‐5 days preoperatively, and then 2 g/d postoperatively)
Number of subjects: 1516
Study 30571332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study 30571332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 1516
Study 27415448 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643
Study 27415448 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643
Study 27415448 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam conformal radiotherapy
Number of subjects: 1643
Study 27415448 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1643
Study 25199624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 26722
Study 22574800 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Therapy + Constructive Worry (BT + CW)
Number of subjects: 22
Study 22574800 — intervention group
Group type: COMPARATOR
Intervention: Behaviour Therapy (BT)
Number of subjects: 22
Study 18801827 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE1625 (20 mg)
Number of subjects: 0
Study 18556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily for 6 months)
Number of subjects: 120
Study 18556965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 120
Study 16087013 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0‐g dose of azithromycin microsphere formulation
Number of subjects: 507
Study 16087013 — intervention group
Group type: COMPARATOR
Intervention: 10 days of levofloxacin, 500 mg/d
Number of subjects: 507
Study 11937121 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (follitropin alpha)
Number of subjects: 18
Study 11937121 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (follitropin beta)
Number of subjects: 18
Study 11937121 — intervention group
Group type: COMPARATOR
Intervention: urinary FSH
Number of subjects: 18
Study 11937121 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (both types)
Number of subjects: 18
Study 11937121 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH and urinary FSH
Number of subjects: 18
Study 11577787 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized pharmacotherapy for GAD
Number of subjects: 0
Study 11577787 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent with demonstrated effectiveness for GAD
Number of subjects: 0
Study 11577787 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate dosing and duration of treatment
Number of subjects: 0
Study 11577787 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive strategies for refractory patients
Number of subjects: 0
Study 9164894 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodes of ventricular fibrillation with intracardiac defibrillation
Number of subjects: 0
Study 9164894 — intervention group
Group type: COMPARATOR
Intervention: External direct-current conversion of atrial fibrillation using high energies
Number of subjects: 0
Study 9164894 — intervention group
Group type: COMPARATOR
Intervention: Pace-terminated ventricular tachycardia
Number of subjects: 0
Study 8500243 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8500243 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine plus isosorbide dinitrate
Number of subjects: 0
Study 3554886 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-eight bandage
Number of subjects: 79
Study 3554886 — intervention group
Group type: COMPARATOR
Intervention: Simple sling
Number of subjects: 79
Study 31972397 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative music therapy (CMT)
Number of subjects: 82
Study 31972397 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 82
Study 29574701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel 12 mg
Number of subjects: 1218
Study 27364955 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg piragliatin twice daily
Number of subjects: 42
Study 27364955 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg piragliatin twice daily
Number of subjects: 42
Study 27364955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27364955 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin
Number of subjects: 42
Study 26573451 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 39
Study 23611405 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Number of subjects: 158
Study 23611405 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Number of subjects: 158
Study 23611405 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy/radiotherapy (CT/TRT) with docetaxel 20 mg/m² and carboplatin AUC 2 weekly plus 60 Gy TRT
Number of subjects: 158
Study 23611405 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 158
Study 23611405 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and concurrent CT/TRT
Number of subjects: 158
Study 23611405 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy and concurrent CT/TRT
Number of subjects: 158
Study 21566289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel titanium compression anastomosis clip
Number of subjects: 51
Study 21566289 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 51
Study 18287590 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (32.9 +/- 3.5 mg)
Number of subjects: 37
Study 18287590 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (96.4 +/- 15.9 mg)
Number of subjects: 37
Study 17523575 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Focus and Symptom Management Intervention (AFSMI)
Number of subjects: 117
Study 17523575 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 117
Study 12943942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 187
Study 12943942 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 187
Study 12943942 — intervention group
Group type: COMPARATOR
Intervention: HDRS score of 8
Number of subjects: 187
Study 12943942 — intervention group
Group type: COMPARATOR
Intervention: MADRS score of 14
Number of subjects: 187
Study 12943942 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% reduction in HDRS and MADRS scores
Number of subjects: 187
Study 12943942 — intervention group
Group type: COMPARATOR
Intervention: 50% reduction in HDRS and MADRS scores
Number of subjects: 187
Study 11105738 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of enteric‐coated fluoxetine weekly
Number of subjects: 501
Study 11105738 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine daily
Number of subjects: 501
Study 11105738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 11105738 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of enteric‐coated fluoxetine weekly and 20 mg daily fluoxetine
Number of subjects: 501
Study 9196864 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (5-day infusion at 2.0 ng/kg per minute for 8 hours per day, followed by a 1-day infusion every 6 weeks)
Number of subjects: 31
Study 9196864 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily, oral slow-release formulation)
Number of subjects: 31
Study 9196864 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 31
Study 1343607 — intervention group
Group type: EXPERIMENTAL
Intervention: Online journals
Number of subjects: 0
Study 1343607 — intervention group
Group type: COMPARATOR
Intervention: Printed journals
Number of subjects: 0
Study 30253405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 6 months post-VIU
Number of subjects: 60
Study 30253405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 60
Study 28707034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser photocoagulation
Number of subjects: 72
Study 28707034 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocautery
Number of subjects: 72
Study 26286039 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for occupational physicians to enhance adherence to mental health guidelines
Number of subjects: 128
Study 26286039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 128
Study 26286039 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline RTW self-efficacy scores
Number of subjects: 128
Study 23520900 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal counselling
Number of subjects: 86
Study 23520900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 86
Study 21419609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystone(®)
Number of subjects: 10
Study 21419609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18667843 — intervention group
Group type: EXPERIMENTAL
Intervention: New bath oil containing St. John's wort extract
Number of subjects: 18
Study 18667843 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial bath oil 1
Number of subjects: 18
Study 18667843 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial bath oil 2
Number of subjects: 18
Study 18667843 — intervention group
Group type: COMPARATOR
Intervention: 1% vol/vol sodium lauryl sulfate (SLS)
Number of subjects: 18
Study 18667843 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 18
Study 16326163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet based on the FDA Tips for the Savvy Supplement User
Number of subjects: 113
Study 16326163 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 113
Study 14671473 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized developmental care
Number of subjects: 92
Study 11289500 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy alone (average TT: 22.2%)
Number of subjects: 170
Study 11289500 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy with antiplatelet agent (average TT: 20.9%)
Number of subjects: 170
Study 11289500 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with thromboembolism (average TT: 26.4%, PT-INR: 1.53)
Number of subjects: 170
Study 11289500 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without thromboembolism (average TT: 21.1%, PT-INR: 1.73)
Number of subjects: 170
Study 9001879 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 30
Study 9001879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9001879 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (for non-responders from placebo)
Number of subjects: 30
Study 1458789 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (3.6 g per day)
Number of subjects: 32
Study 1458789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3881108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 990 mg and dipyridamole 225 mg daily
Number of subjects: 320
Study 3881108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 3881108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 320
Study 31378215 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP-Family (n = 49)
Number of subjects: 93
Study 31378215 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (n = 44)
Number of subjects: 93
Study 30155910 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal psychological distress
Number of subjects: 669
Study 30155910 — intervention group
Group type: EXPERIMENTAL
Intervention: Harsh discipline
Number of subjects: 669
Study 30155910 — intervention group
Group type: EXPERIMENTAL
Intervention: Overinvolved parenting
Number of subjects: 669
Study 30155910 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mental health
Number of subjects: 669
Study 30155910 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult child temperament
Number of subjects: 669
Study 27198973 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 3066
Study 27198973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3066
Study 24792139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glides (SNAGs) with self-SNAG exercises
Number of subjects: 86
Study 24792139 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive joint mobilization (PJM) with ROM exercises
Number of subjects: 86
Study 24792139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glides (SNAGs)
Number of subjects: 86
Study 24792139 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (SNAGs and PJM)
Number of subjects: 86
Study 22960461 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% xylitol mouthrinse
Number of subjects: 50
Study 22960461 — intervention group
Group type: COMPARATOR
Intervention: Saccharine mouthrinse (control)
Number of subjects: 50
Study 19661817 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD (T-EGD)
Number of subjects: 300
Study 19661817 — intervention group
Group type: COMPARATOR
Intervention: Conventional EGD without sedation (C-EGD)
Number of subjects: 300
Study 19661817 — intervention group
Group type: COMPARATOR
Intervention: Conventional EGD with sedation (CS-EGD)
Number of subjects: 300
Study 16448280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets bonded with self-etching adhesive (3M Transbond Plus Self-etching primer)
Number of subjects: 62
Study 16448280 — intervention group
Group type: COMPARATOR
Intervention: Edgewise brackets bonded with conventional acid etching (Orthosolo primer and Enlight paste)
Number of subjects: 62
Study 16335772 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention including nutrition, health and literacy education for mothers, improved growth monitoring, fostering rural cooperatives and income generation schemes.
Number of subjects: 0
Study 16335772 — intervention group
Group type: COMPARATOR
Intervention: Control areas (no specific intervention mentioned).
Number of subjects: 0
Study 11125687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ketamine 0.5 mg/kg diluted with saline up to 5 mL
Number of subjects: 60
Study 11125687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-muscular ketamine 0.5 mg/kg
Number of subjects: 60
Study 11125687 — intervention group
Group type: COMPARATOR
Intervention: Saline 5 mL intra-articularly (control)
Number of subjects: 60
Study 9334157 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial structures
Number of subjects: 14
Study 9334157 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority of cells
Number of subjects: 14
Study 9334157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cells of myxoid areas
Number of subjects: 14
Study 9334157 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrous areas
Number of subjects: 14
Study 9334157 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of ECM
Number of subjects: 14
Study 8420041 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 3
Study 8420041 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐ALG
Number of subjects: 3
Study 8420041 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 3
Study 3526500 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine treatment
Number of subjects: 0
Study 3526500 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 30379749 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressors (Norepinephrine, epinephrine, metaraminol, or vasopressin)
Number of subjects: 1588
Study 28121470 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheatgrass (Triticum aestivum L.) 3.5 g freeze-dried powder daily for 10 weeks
Number of subjects: 59
Study 28121470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 24989067 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Mobilizations (3 weeks, two sessions per week)
Number of subjects: 90
Study 24989067 — intervention group
Group type: COMPARATOR
Intervention: Sham Mobilizations (same duration as joint mobilization)
Number of subjects: 90
Study 24989067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 23832863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 µg/kg SPA (n = 8)
Number of subjects: 20
Study 23832863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 µg/kg SPA (n = 8)
Number of subjects: 20
Study 23832863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 20
Study 23832863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 µg/kg and 0.45 µg/kg SPA
Number of subjects: 20
Study 22111826 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen saphenous vein A-V fistula
Number of subjects: 70
Study 22111826 — intervention group
Group type: COMPARATOR
Intervention: Gore-tex A-V fistula
Number of subjects: 70
Study 19249698 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaginal hysterectomy method; details on dosage and duration not applicable.
Number of subjects: 0
Study 19249698 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical methods; details on dosage and duration not applicable.
Number of subjects: 0
Study 18666468 — intervention group
Group type: EXPERIMENTAL
Intervention: Triac (19.6 ug/kg)
Number of subjects: 36
Study 18666468 — intervention group
Group type: COMPARATOR
Intervention: L-T4 (1.7 ug/kg)
Number of subjects: 36
Study 16479742 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide cream
Number of subjects: 189
Study 16479742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 12160574 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions without blanking
Number of subjects: 0
Study 12160574 — intervention group
Group type: COMPARATOR
Intervention: Conditions with blanking (60 ms)
Number of subjects: 0
Study 12160574 — intervention group
Group type: COMPARATOR
Intervention: Conditions with blanking (220 ms)
Number of subjects: 0
Study 10219333 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 mcg/kg subcutaneous injection daily from day 9 until neutrophil count exceeds 0.5 x 10(9)/l for 3 days)
Number of subjects: 17
Study 10219333 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 17
Study 10219333 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF after second intensification
Number of subjects: 17
Study 7834973 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol in polypropylene containers
Number of subjects: 1481
Study 7834973 — intervention group
Group type: COMPARATOR
Intervention: Iohexol in glass vials
Number of subjects: 1481
Study 2114414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetyl salicylate (Aspergesic) 1.8 g t.d.s.
Number of subjects: 24
Study 2114414 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg t.d.s.
Number of subjects: 24
Study 352094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopenthixol decanoate
Number of subjects: 21
Study 30806492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Treatment (ABT)
Number of subjects: 190
Study 30806492 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 190
Study 27283365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral bovine colostrum, four times a day, till 21 days of life or discharge or death
Number of subjects: 86
Study 27283365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86